HRP20180122T1 - Derivat pirazina - Google Patents
Derivat pirazina Download PDFInfo
- Publication number
- HRP20180122T1 HRP20180122T1 HRP20180122TT HRP20180122T HRP20180122T1 HR P20180122 T1 HRP20180122 T1 HR P20180122T1 HR P20180122T T HRP20180122T T HR P20180122TT HR P20180122 T HRP20180122 T HR P20180122T HR P20180122 T1 HRP20180122 T1 HR P20180122T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- methyl
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014099677 | 2014-05-13 | ||
| EP15792266.7A EP3144306B1 (en) | 2014-05-13 | 2015-05-12 | Pyrazine derivative |
| PCT/JP2015/063654 WO2015174417A1 (ja) | 2014-05-13 | 2015-05-12 | ピラジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180122T1 true HRP20180122T1 (hr) | 2018-02-23 |
Family
ID=54479954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180122TT HRP20180122T1 (hr) | 2014-05-13 | 2015-05-12 | Derivat pirazina |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9856237B2 (enExample) |
| EP (1) | EP3144306B1 (enExample) |
| JP (1) | JP6173576B2 (enExample) |
| KR (1) | KR20170004998A (enExample) |
| CN (1) | CN106458998A (enExample) |
| AR (1) | AR100403A1 (enExample) |
| AU (1) | AU2015260300A1 (enExample) |
| CA (1) | CA2948797A1 (enExample) |
| CY (1) | CY1119876T1 (enExample) |
| DK (1) | DK3144306T3 (enExample) |
| ES (1) | ES2654434T3 (enExample) |
| HR (1) | HRP20180122T1 (enExample) |
| HU (1) | HUE035728T2 (enExample) |
| IL (1) | IL248900A0 (enExample) |
| LT (1) | LT3144306T (enExample) |
| ME (1) | ME02978B (enExample) |
| MX (1) | MX2016014693A (enExample) |
| NO (1) | NO3144306T3 (enExample) |
| PH (1) | PH12016502223A1 (enExample) |
| PL (1) | PL3144306T3 (enExample) |
| PT (1) | PT3144306T (enExample) |
| RS (1) | RS56837B1 (enExample) |
| RU (1) | RU2016148735A (enExample) |
| SG (1) | SG11201609359WA (enExample) |
| SI (1) | SI3144306T1 (enExample) |
| SM (1) | SMT201800155T1 (enExample) |
| TW (1) | TW201609702A (enExample) |
| WO (1) | WO2015174417A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN116496198A (zh) * | 2023-06-26 | 2023-07-28 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种4-羟基-2'-(1-苄基-5-硝基吡咯甲叉)-苯甲酰肼衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034922A1 (en) * | 1997-02-05 | 1998-08-13 | Sankyo Company, Limited | Prophylactic or therapeutic agent for diabetic complication |
| JP4397875B2 (ja) * | 1997-02-05 | 2010-01-13 | 第一三共株式会社 | 糖尿病合併症予防薬又は治療薬 |
| CN101012193A (zh) * | 2003-01-02 | 2007-08-08 | 霍夫曼-拉罗奇有限公司 | 新cb 1受体反激动剂 |
| JP2007145786A (ja) * | 2005-11-30 | 2007-06-14 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| JP5378988B2 (ja) | 2007-04-11 | 2013-12-25 | キッセイ薬品工業株式会社 | ５員環へテロ環誘導体及びその医薬用途 |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| KR20150082194A (ko) | 2012-11-14 | 2015-07-15 | 데이진 화-마 가부시키가이샤 | 피리딘 유도체 |
-
2015
- 2015-05-12 NO NO15792266A patent/NO3144306T3/no unknown
- 2015-05-12 CA CA2948797A patent/CA2948797A1/en not_active Abandoned
- 2015-05-12 TW TW104115028A patent/TW201609702A/zh unknown
- 2015-05-12 CN CN201580024718.7A patent/CN106458998A/zh active Pending
- 2015-05-12 LT LTEP15792266.7T patent/LT3144306T/lt unknown
- 2015-05-12 SM SM20180155T patent/SMT201800155T1/it unknown
- 2015-05-12 US US15/310,337 patent/US9856237B2/en not_active Expired - Fee Related
- 2015-05-12 PL PL15792266T patent/PL3144306T3/pl unknown
- 2015-05-12 RS RS20180019A patent/RS56837B1/sr unknown
- 2015-05-12 JP JP2016519266A patent/JP6173576B2/ja not_active Expired - Fee Related
- 2015-05-12 EP EP15792266.7A patent/EP3144306B1/en active Active
- 2015-05-12 SG SG11201609359WA patent/SG11201609359WA/en unknown
- 2015-05-12 MX MX2016014693A patent/MX2016014693A/es unknown
- 2015-05-12 PT PT157922667T patent/PT3144306T/pt unknown
- 2015-05-12 AU AU2015260300A patent/AU2015260300A1/en not_active Abandoned
- 2015-05-12 ME MEP-2018-5A patent/ME02978B/me unknown
- 2015-05-12 DK DK15792266.7T patent/DK3144306T3/en active
- 2015-05-12 HR HRP20180122TT patent/HRP20180122T1/hr unknown
- 2015-05-12 ES ES15792266.7T patent/ES2654434T3/es active Active
- 2015-05-12 KR KR1020167031523A patent/KR20170004998A/ko not_active Withdrawn
- 2015-05-12 SI SI201530130T patent/SI3144306T1/en unknown
- 2015-05-12 RU RU2016148735A patent/RU2016148735A/ru not_active Application Discontinuation
- 2015-05-12 HU HUE15792266A patent/HUE035728T2/en unknown
- 2015-05-12 WO PCT/JP2015/063654 patent/WO2015174417A1/ja not_active Ceased
- 2015-05-12 AR ARP150101453A patent/AR100403A1/es unknown
-
2016
- 2016-11-09 PH PH12016502223A patent/PH12016502223A1/en unknown
- 2016-11-10 IL IL248900A patent/IL248900A0/en unknown
-
2018
- 2018-02-01 CY CY20181100126T patent/CY1119876T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170004998A (ko) | 2017-01-11 |
| IL248900A0 (en) | 2017-01-31 |
| EP3144306B1 (en) | 2017-11-15 |
| ME02978B (me) | 2018-10-20 |
| AR100403A1 (es) | 2016-10-05 |
| PL3144306T3 (pl) | 2018-04-30 |
| WO2015174417A1 (ja) | 2015-11-19 |
| AU2015260300A1 (en) | 2016-12-22 |
| SG11201609359WA (en) | 2016-12-29 |
| PT3144306T (pt) | 2018-01-08 |
| HUE035728T2 (en) | 2018-05-28 |
| JP6173576B2 (ja) | 2017-08-02 |
| JPWO2015174417A1 (ja) | 2017-04-20 |
| MX2016014693A (es) | 2017-02-23 |
| US9856237B2 (en) | 2018-01-02 |
| EP3144306A1 (en) | 2017-03-22 |
| EP3144306A4 (en) | 2017-03-22 |
| CA2948797A1 (en) | 2015-11-19 |
| LT3144306T (lt) | 2018-01-10 |
| PH12016502223A1 (en) | 2017-02-06 |
| DK3144306T3 (en) | 2018-01-02 |
| TW201609702A (zh) | 2016-03-16 |
| RS56837B1 (sr) | 2018-04-30 |
| CN106458998A (zh) | 2017-02-22 |
| SI3144306T1 (en) | 2018-02-28 |
| ES2654434T3 (es) | 2018-02-13 |
| CY1119876T1 (el) | 2018-06-27 |
| RU2016148735A (ru) | 2018-06-19 |
| RU2016148735A3 (enExample) | 2018-06-19 |
| SMT201800155T1 (it) | 2018-05-02 |
| US20170152242A1 (en) | 2017-06-01 |
| NO3144306T3 (enExample) | 2018-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506962A5 (enExample) | ||
| NZ610746A (en) | Methods of treatment using selective bcl-2 inhibitors | |
| FI3897636T3 (fi) | Substituoituja 3-((3-aminofenyyli)amino)piperidiini-2,6-dioniyhdisteitä, niiden koostumuksia ja menetelmiä niillä annettavia hoitoja varten | |
| JP2016512520A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| CY1117751T1 (el) | Αναστολεις βενζιμιδαζολης αναπνευστικου συγκυτιακου ιου | |
| SI2978752T1 (en) | 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD | |
| JP2012509263A5 (enExample) | ||
| TW201613568A (en) | Pharmaceutical composition comprising novel hydroxamic acid derivative or salt thereof | |
| EA201100030A1 (ru) | Пиразольные соединения 436 | |
| JP2013543896A5 (enExample) | ||
| ME02373B (me) | Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze | |
| JP2012507535A5 (enExample) | ||
| MX2017007748A (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk). | |
| CL2012001133A1 (es) | Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo. | |
| JP2011529054A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| JP2018048143A5 (enExample) | ||
| RU2015155585A (ru) | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента | |
| NZ612544A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич | |
| CN111601791A (zh) | Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用 |